Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Better approach for autoimmune pulmonary alveolar proteinosis treatment: inhaled or subcutaneous granulocyte-macrophage colony-stimulating factor: a meta-analyses

Fig. 2

Forest plot shows the pooled outcomes of granulocyte macrophage colony stimulating factor (GM-CSF) therapy in patients with autoimmune pulmonary alveolar proteinosis (aPAP). a. Response rate of GM-CSF therapy (81%, 95% CI: 65–96%, p < 0.001). b. Relapse rate of GM-CSF therapy (22%, 95% CI: 6–39%, p = 0.009). c. Alveolar oxygen partial pressure (PaO2) improved by 13.76 mmHg (95% CI: 7.81–19.72, p < 0.001) after GM-CSF therapy. d. Alveolar-arterial oxygen gradient (P(A-a)O2) decreased by 19.44 mmHg (95% CI: 13.42–25.46, p < 0.001) after GM-CSF therapy

Back to article page